Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

Veracyte (Nasdaq: VCYT) announced six studies involving its genomic tests will be presented at ESMO 2026, October 23–27 in Madrid.

Rhea-AI Summary

Veracyte (Nasdaq: VCYT) announced six studies involving its genomic tests will be presented at ESMO 2026, October 23–27 in Madrid.

The presentations cover prostate and bladder cancer treatment selection and risk assessment, plus breast cancer health economics. Veracyte said a Decipher Prostate oral presentation will provide the first evidence that the test predicts benefit from adding abiraterone to androgen deprivation therapy for clinically very high-risk, nonmetastatic prostate cancer. A separate late-breaking oral presentation will report a two-year, within-trial economic analysis of Prosigna-guided chemotherapy decisions in the Phase III OPTIMA breast cancer trial. Four posters address additional prostate and bladder cancer research.

Argus 15 min delay 2 alerts

+1.07% vs previous close $43.58 last price 0.4x rel. volume Open Argus

Details

Market Reaction – VCYT

$43.08 – $45.01 Day Range

$3.50B Mkt Cap at Last Price

On Oct 19, the day this news came out, the latest delayed price for VCYT is 1.07% above the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $43.58.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Studies presented: 6 studies Trial phase: Phase III Assay size: 50-gene assay +1 more

Studies presented

6 studies

At ESMO 2026

Trial phase

Phase III

OPTIMA breast cancer trial

Assay size

50-gene assay

OPTIMA within-trial economic analysis

Results period

2-year results

OPTIMA randomised trial

Historical Context

2 past events · Latest: Sep 29

2 events

1. Sep 29

   clinical trial

   24h Move

   +1.9%

   Phase III analysis found Decipher predicted benefit from adding hormone therapy to radiation.

2. Oct 16

   Medicare coverage

   24h Move

   -2.9%

   Medicare covered Prosigna; OPTIMA showed chemotherapy could be spared for more than two-thirds without compromising outcomes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

androgen deprivation therapy, transcriptome classifier, androgen receptor pathway inhibitors, urothelial carcinoma

4 terms

androgen deprivation therapy medical

"adding abiraterone to androgen deprivation therapy"

Androgen deprivation therapy is a medical treatment that lowers or blocks male hormones (androgens) to slow the growth of hormone-sensitive cancers, most commonly prostate cancer. Think of it as cutting off the fuel a fire needs so the blaze slows; for investors, changes in ADT use, new ADT drugs, or clinical trial results can affect demand for medications, device procedures, safety profiles and long-term revenue for healthcare companies.

transcriptome classifier medical

"Transcriptome classifier risk stratification"

A transcriptome classifier is a diagnostic or research tool that uses patterns of gene expression across all or many RNA transcripts in a biological sample to assign that sample to a category (for example, a disease subtype, tissue type, or risk group). It is built by training statistical or machine‑learning models on labeled gene‑expression data so the classifier learns which combinations of RNA levels distinguish the categories; its performance depends on the quality of the training data, the platform used to measure RNA, and independent validation or regulatory clearance if intended for clinical use.

androgen receptor pathway inhibitors medical

"intensification with androgen receptor pathway inhibitors"

Drugs that block signals sent through the androgen receptor, a cellular “antenna” that many tumors—most notably prostate cancers—use to grow and survive. By cutting off that fuel line, these medicines can slow or shrink tumors; for investors, trial results, regulatory approvals, safety data and patent position for such drugs can sharply change a biotech or drugmaker’s value, similar to how a single new engine can transform a vehicle’s performance.

urothelial carcinoma medical

"Age at Diagnosis as an Independent Prognostic Factor in Urothelial Carcinoma"

Urothelial carcinoma is a type of cancer that starts in the urothelial cells lining the bladder and other parts of the urinary tract; imagine the inner lining of a pipe developing patches of damage that grow into invasive tissue. It matters to investors because its prevalence, available treatments, and clinical trial outcomes drive demand for new drugs, influence regulatory approvals and reimbursement decisions, and can materially affect the revenue and valuation of companies developing therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysis

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The presentations span treatment selection and risk assessment in prostate and bladder cancer, as well as a late-breaking health economic analysis from the Phase III landmark OPTIMA breast cancer trial.

A prostate cancer oral presentation will provide the first evidence that the Decipher Prostate test predicts benefit from adding abiraterone to androgen deprivation therapy for patients with clinically very high-risk, nonmetastatic disease. The findings extend Decipher’s predictive evidence into another treatment setting and build on its established role in prostate cancer risk stratification and treatment benefit. A separate oral presentation will report a within-trial economic analysis of Prosigna-guided chemotherapy decisions in OPTIMA.

“The research being presented at ESMO reflects how understanding a tumor’s biology can inform decisions across cancer care,” said Phillip Febbo, M.D., Veracyte’s chief scientific and medical officer. “The Decipher Prostate study will provide the first evidence that the test predicts benefit from adding abiraterone to treatment for patients with clinically very high-risk disease. Alongside the OPTIMA economic analysis and new bladder cancer research, these studies address questions that matter to patients and clinicians.”

Veracyte-related presentations at ESMO 2026

Oral presentations:

Title: Transcriptome classifier risk stratification and intensification with androgen receptor pathway inhibitors (ARPI) for clinically very high-risk prostate cancer (PCa)

• Presenter: Sarah Howlett, M.B.B.S., Clinical Research Fellow, Research Department of Oncology, University College London  
• Abstract #: 2045O
• Date and time: Saturday, October 24, 10:15–11:45 a.m. CEST
• Location: Barcelona Auditorium, Hall 9

Late-breaking oral presentation:

Title: Within-trial economic analysis of chemotherapy for high-risk early breast cancer informed by a 50-gene assay: 2-year results from the OPTIMA randomised trial

• Presenter: Peter Hall, M.B.Ch.B., Ph.D., Professor of Medical Oncology (Cancer Informatics), University of Edinburgh
• Abstract #: LBA86
• Date and time: Sunday, October 25, 10:15 a.m. – 11:45am CET
• Location: Seville Auditorium - NCC

Poster presentations

Title: Age at Diagnosis as an Independent Prognostic Factor in Urothelial Carcinoma: Impact on Survival and Immune Microenvironment Within Molecular Subtypes

• Presenter: Michela Piacentini, M.D., Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan
• Abstract #: 4746P
• Date and time: Friday, October 23, 3:15–4:00 p.m. CEST
  

Title: Prognostic Value of the Decipher Prostate Genomic Classifier (GC) and Neuroendocrine (NE) Gene Expression Signatures in Real-World De Novo Metastatic (M1) Prostate Cancer

• Presenter: Alice Bernard-Tessier, M.D., medical oncologist, Gustave Roussy; Research Fellow, Dana-Farber Cancer Institute
• Abstract #: 4465P
• Date and time: Friday, October 23, 3:15–4:00 p.m. CEST
  

Title: A Scar-like Transcriptomic Classifier Confirms Favorable Outcomes in Patients with Residual Bladder Cancer (BC) after Perioperative Chemo-immunotherapy

• Presenter: Chiara Mercinelli, M.D., Medical Oncologist, IRCCS San Raffaele Hospital and Scientific Institute, Milan
• Abstract #: 4521eP
• Date and time: electronic poster
  

Title: Evaluating the prognostic utility of a genomic classifier (GC) in an Asian real-world cohort of localized prostate cancer (PCa)

• Presenter: Melvin Lee Kiang Chua, M.B.B.S., Ph.D., Head and Senior Consultant, National Cancer Centre Singapore; Professor, Duke-NUS Medical School
• Abstract #: 2061eP
• Date and time: electronic poster
  

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to the role of Veracyte’s genomic tests in informing treatment selection, risk assessment and other decisions across cancer care; the anticipated clinical utility, performance and potential impact of Veracyte’s genomic tests; and the potential for the Decipher Prostate Genomic Classifier to predict benefit from adding abiraterone to androgen-deprivation therapy in patients with clinically very high-risk, nonmetastatic prostate cancer. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at Veracyte Investor Relations. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780